TGM2 and Cowden disease: In 2012, ESPGHAN introduced a new possibility of establishing CD diagnosis without intestinal biopsy in children and adolescents with CD symptoms [10], and in 2020, even in those at-risk groups without such symptoms, who have high (>10 times upper limit of normal, ULN) TG2 IgA concentration in sera.